For Employers
GLP‑1s Cover Some of Your Employees. Signos Covers All of Them.
Signos delivers FDA-cleared continuous glucose monitoring (CGM) powered by AI, giving you unprecedented visibility into employee adoption, outcomes, and ROI. Empower your workforce with sustainable weight management, without the costly GLP‑1 decision.
11x
Daily Engagement
Employees open the app 11x daily
86%
Success Rate
Within the first month of usage
25%
Claims Reduction
Proven in employer program results
Metabolic Health and Weight Management Strategy for Your Entire Population
Signos is venture-backed by Google, Dexcom, and Samsung—redefining metabolic weight management for enterprise employers. Our AI platform, built on FDA-cleared glucose monitoring system, regulates metabolism 24/7 in real time. Promotes micro-behavioral changes that stick, even after graduating from a GLP‑1. Serving as a first-line defense against escalating specialty drug costs.
Real-Time ROI Visibility
Provide your organization with real-time data on adoption and outcomes for the entire workforce, not just high-risk members. This supports preventative care and proactively avoids costly claims.
Turnkey Deployment
No integrations needed. Deploy in weeks with streamlined contracting—minimal lift for your team, maximum impact for your population. We handle the complexity.
Scalable & Complementary
Works alongside GLP‑1s or other programs, across populations from healthy to non-insulin-dependent type II diabetes with no prescription required.
Unmatched Engagement
With an average tenure of 9 months, employees use the app 11x a day, demonstrating significant adoption within our overweight and obese cohorts.
Real-Time Population Health Visibility
Why wait for a QBR when your population is changing right now?
The only platform delivering continuous metabolic and behavioral visibility—eliminating guesswork and accelerating outcomes daily, not quarterly.
Always-on Visibility
Workforce health trends and outcomes, whenever you need them.
Data You Can Act On
Real-time insights show what's working. No waiting, no assumptions.
Track Impact
See the impact of healthier habits and metabolic improvements as they happen, not months later.
Drive Sustainable ROI for Your Organization
Signos delivers what traditional wellness programs can't: real-time behavior change you can measure. With continuous glucose monitoring and AI-powered insights, employees see exactly how their choices affect their health—and employers see adoption, adherence, and outcomes as they happen. Scalable across your entire population, from prevention to maintenance.
Savings per Member
Up to 25% reduction in wellness claims
Measurable Progress
15% metabolic improvement in the first 90 days
Activation & Adherence
88% engagement; 9-month average tenure
Real Data. Real Change. Real Members.
Martin T. - Verified Member
Signos rocks...
Less than 3 months and just shy of 30 pounds lost. Interesting to see what food does to you in particular. You are learning about yourself, how things effect you personally. The AI helps prompt you and the lessons help you trial the concept in different ways. It has been quite the experience. Would recommend if you like data and are motivated to improve.
Verified Member
Best investment for lasting results
This is the best investment I have ever made concerning my health. You get to see in real time the opportunities to assist in making positive changes and how your body responds. It's like having my own personal trainer I carry around on my arm. It is a fantastic product.
Kathleen - Verified Member
Down 16lbs and counting
It's a game changer for sure. I'm down 16lbs since December 9th and the invaluable information this device gives you is remarkable. I'm a fan for sure.
HOW IT WORKS
Your Body Runs On Glucose
Signos helps you build healthy habits that stick with clear, personalized guidance:
See how your body responds in real time with glucose insights
Learn what (and when) to eat to curb cravings and feel satisfied
Get gentle, expert-led coaching that keeps you motivated
Build simple, sustainable habits to support long-term weight management
Venture backed partner of
Cover Your Whole Population
Already a Signos provider? Log in to your admin portal
We respect your privacy and protect your data. Review our Privacy Policy—you can unsubscribe at any time.
Supporting Metabolic Health Before, During, and After GLP‑1s
Download the full guide and learn how Signos enables organizations to improve population metabolic health and support long-term goals while on a GLP‑1 and as they graduate off.
Don't miss out!
Sign up to be the first to know about special offers and exciting Signos news.
Copyright © 2026 Signos Inc.
Signos indications: The Signos Glucose Monitoring System is an over-the-counter (OTC) mobile device application that receives data from an integrated Continuous Glucose Monitor (iCGM) sensor and is intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Signos Glucose Monitoring System helps to detect normal (euglycemic) and low or high (dysglycemic) glucose levels. The Signos Glucose Monitoring System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursions. This information may be useful in helping users to maintain a healthy weight.
The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.
See user guide for important warnings and precautions.
STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency.
STELO INDICATIONS FOR USE: The Stelo Glucose Biosensor System is an over-the-counter (OTC) integrated Continuous Glucose Monitor (iCGM) intended to continuously measure, record, analyze, and display glucose values in people 18 years and older not on insulin. The Stelo Glucose Biosensor System helps to detect normal (euglycemic) and low or high (dysglycemic) glucose levels. The Stelo Glucose Biosensor System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursion. The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.
OPENLOOP CLINICAL AND PHARMACEUTICAL SERVICES:
Signos is a technology platform and wellness program provider. With the exception of registered dieticians, Signos does not employ licensed health care professionals to practice medicine, does not diagnose, treat, cure, or prevent any disease or medical condition, and does not provide medical advice. You should always consult your own health care professional for diagnosis, treatment, and care regarding any medical condition or health concern. Clinical services accessible through the Signos platform are provided solely by OpenLoop Health and other independent networks of U.S.-licensed clinicians, who exercise their own independent medical judgment to determine eligibility for GLP‑1 treatment based on medical history and assessment responses. These independent providers retain full discretion to prescribe or decline compounded GLP‑1 medications. Signos does not direct, control, or influence any clinical decision made by these providers, and no provider-patient relationship is created between you and Signos.
Compounded medications that may be made available in connection with the Signos program are produced in FDA-registered facilities, but are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. Signos does not manufacture, compound, dispense, or distribute any medications. Signos partners with certified U.S. pharmacies to help facilitate access to these medications, but Signos makes no representations or warranties regarding the safety, efficacy, suitability, or quality of any compounded medication. Product appearance may differ from website images.
Medication costs are included in the Signos program; however, inclusion of medication costs does not constitute the practice of medicine or pharmacy by Signos. Results may vary and depend on individual adherence, independent provider guidance, and lifestyle changes. Unless otherwise noted, results referenced reflect individual Signos patient experiences rather than public clinical studies, and no particular outcome is guaranteed.
Nothing on this website or within the Signos platform should be construed as medical advice, a medical diagnosis, or a recommendation for any specific treatment. If you are experiencing a medical emergency, call 911 or your local emergency services immediately.